MA44862A - Formulations de fulvestrant et méthodes d'utilisation de celles-ci - Google Patents

Formulations de fulvestrant et méthodes d'utilisation de celles-ci

Info

Publication number
MA44862A
MA44862A MA044862A MA44862A MA44862A MA 44862 A MA44862 A MA 44862A MA 044862 A MA044862 A MA 044862A MA 44862 A MA44862 A MA 44862A MA 44862 A MA44862 A MA 44862A
Authority
MA
Morocco
Prior art keywords
methods
fulvestrant formulations
fulvestrant
formulations
Prior art date
Application number
MA044862A
Other languages
English (en)
Inventor
Feng-Jing Chen
Steven L Krill
Rama Abu Shmeis
Original Assignee
Eagle Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Pharmaceuticals Inc filed Critical Eagle Pharmaceuticals Inc
Publication of MA44862A publication Critical patent/MA44862A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA044862A 2016-05-06 2017-05-05 Formulations de fulvestrant et méthodes d'utilisation de celles-ci MA44862A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662332842P 2016-05-06 2016-05-06
US201662420555P 2016-11-10 2016-11-10

Publications (1)

Publication Number Publication Date
MA44862A true MA44862A (fr) 2019-03-13

Family

ID=58709642

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044862A MA44862A (fr) 2016-05-06 2017-05-05 Formulations de fulvestrant et méthodes d'utilisation de celles-ci

Country Status (15)

Country Link
US (2) US20190134059A1 (fr)
EP (1) EP3452011A1 (fr)
JP (3) JP2019516789A (fr)
KR (1) KR102438425B1 (fr)
CN (1) CN109310621A (fr)
AU (2) AU2017261321B2 (fr)
CA (1) CA3022834A1 (fr)
CO (1) CO2018013257A2 (fr)
IL (2) IL285928B2 (fr)
MA (1) MA44862A (fr)
MX (2) MX2018013414A (fr)
MY (1) MY205661A (fr)
UA (1) UA125514C2 (fr)
WO (1) WO2017193048A1 (fr)
ZA (1) ZA201807031B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
JP7220712B2 (ja) * 2017-11-08 2023-02-10 イーグル ファーマスーティカルズ、インク. フルベストラント製剤とその使用方法
EP4074304A4 (fr) * 2019-12-11 2024-01-10 Shanghai Bocimed Pharmaceutical Co., Ltd. Composition pharmaceutique de fulvestrant, procédé de préparation et application de celle-ci
CN113694017B (zh) * 2020-05-11 2024-04-02 鲁南制药集团股份有限公司 一种氟维司群注射制剂及其制备方法
WO2022100750A1 (fr) * 2020-11-16 2022-05-19 北京厚燊维康科技有限责任公司 Préparation disponible pour une thérapie ou un diagnostic photodynamique
CN120284882A (zh) * 2020-12-10 2025-07-11 上海云晟研新生物科技有限公司 氟维司群药物组合物、其制备方法及应用
KR20230094172A (ko) * 2021-12-20 2023-06-27 주식회사 삼양홀딩스 용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법
KR20240105964A (ko) * 2022-12-29 2024-07-08 주식회사 삼양홀딩스 약동학적 특성이 우수한 풀베스트란트의 약학 조성물 및 그 제조 방법

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
JP2003533464A (ja) 2000-05-15 2003-11-11 フアルマシア・イタリア・エツセ・ピー・アー 安定化ステロイド懸濁液
HUP0400115A3 (en) * 2001-07-07 2005-11-28 Astrazeneca Ab Pharmaceutical composition for the intramuscular administration of fulvestrant
GB0116619D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
JP2003298516A (ja) 2002-03-29 2003-10-17 Fujitsu Ltd 波長分散補償装置
PL1778187T3 (pl) * 2004-08-04 2012-09-28 Camurus Ab Kompozycje tworzące nielamelarne dyspersje
KR20140090270A (ko) 2005-05-09 2014-07-16 바이오스피어 메디칼 에스.에이. 마이크로스피어 및 비이온성 조영제를 사용하는 조성물 및 방법
BRPI0617663A2 (pt) 2005-10-21 2011-08-02 Panacea Biotec Ltd composições aperfeiçoadas para terapia de cáncer
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN101108168B (zh) * 2007-08-03 2010-12-08 西安力邦医药科技有限责任公司 一种氟维司群缓释微球的制备方法
DK2200588T3 (da) 2007-09-25 2019-07-01 Solubest Ltd Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf
JP2011514349A (ja) 2008-03-07 2011-05-06 サイドース・エルエルシー フルベストラント配合物
TW201016220A (en) * 2008-10-31 2010-05-01 Scinopharm Taiwan Ltd Micronization form of 7α-[9-(4,4,5,5,5-pentafluoropentylsufinyl)nonyl]estra-1,3,5(10)-triene-3,17β-diol and process for the preparation thereof
KR20120052937A (ko) * 2009-06-18 2012-05-24 아보트 러보러터리즈 안정한 나노입자형 약물 현탁액
AU2010278601A1 (en) * 2009-07-31 2012-02-23 Xi'an Libang Medical Technology Co., Ltd Nanosphere or microsphere drug carrier, preparation method, composition and use thereof
EP2417975A4 (fr) * 2009-08-31 2012-11-14 Xi An Libang Medical Technology Co Ltd Nanosphère/microsphère de fulvestrant, procédé de préparation et utilisation associés
WO2012021791A2 (fr) 2010-08-13 2012-02-16 Scidose Llc Formulation aqueuse à stabilité améliorée
CA2811258C (fr) 2010-09-16 2019-10-15 Shimoda Biotech (Pty) Ltd Compositions a base de fulvestrant, et procedes d'utilisation
EP2468258A1 (fr) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Procédé de préparation d'une composition pharmaceutique comportant un ingrédient actif pharmaceutiquement faiblement soluble
JP6092121B2 (ja) 2011-01-09 2017-03-08 エイエヌピー テクノロジーズ, インコーポレイテッド 疎水性分子に誘起された分岐ポリマー凝集体及びその使用
ES2708302T3 (es) * 2011-05-20 2019-04-09 Capital Business Y Gestion De Finanzas S L Composición farmacéutica
CN102915088A (zh) 2011-08-03 2013-02-06 鸿富锦精密工业(深圳)有限公司 资料存储器固定装置
ES2983451T3 (es) 2012-04-09 2024-10-23 Eagle Pharmaceuticals Inc Formulaciones de Fulvestrant
US11179468B2 (en) * 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
BR112014028376A2 (pt) * 2012-06-08 2018-04-24 Hoffmann La Roche métodos para o tratamento de um distúrbio hiperproliferativo, para a determinação dos compostos, para monitorar, para optimizar a eficácia terapêutica e de identificação de um biomarcador; formulação farmacêutica; utilização de uma combinação terapêutica e de gdc-0032, artigo de manufatura, produto e invenção
CN104337761B (zh) * 2013-08-07 2019-03-26 江苏豪森药业集团有限公司 氟维司群药物组合物
JP2016529308A (ja) * 2013-09-06 2016-09-23 サラー ウッディン アハメド, フルベストラント組成物
CN105745207A (zh) * 2013-10-03 2016-07-06 千年药物公司 使用PI3Kα抑制剂的增强的治疗方案
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
PT107433B (pt) 2014-01-28 2018-12-04 Hovione Farm S A Processo de redução e controlo do tamanho de partícula
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
CA2954064C (fr) 2014-07-02 2018-10-30 The Research Foundation For The State University Of New York Compositions de micelles depouillees d'agent tensioactif a rapport eleve entre charge et agent tensioactif
WO2015018380A2 (fr) 2014-07-03 2015-02-12 Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. Nanoparticules thérapeutiques et leurs procédés de préparation

Also Published As

Publication number Publication date
CA3022834A1 (fr) 2017-11-09
AU2017261321B2 (en) 2023-03-09
US20210346396A1 (en) 2021-11-11
AU2017261321A1 (en) 2018-11-15
KR20190005183A (ko) 2019-01-15
MX2018013414A (es) 2019-06-06
JP2021169510A (ja) 2021-10-28
WO2017193048A1 (fr) 2017-11-09
MY205661A (en) 2024-11-04
EP3452011A1 (fr) 2019-03-13
JP2023109959A (ja) 2023-08-08
CN109310621A (zh) 2019-02-05
ZA201807031B (en) 2023-10-25
CO2018013257A2 (es) 2018-12-28
US12370199B2 (en) 2025-07-29
BR112018072768A2 (pt) 2019-02-19
MX2022013199A (es) 2022-12-13
RU2018142068A3 (fr) 2020-09-17
IL262465A (en) 2018-12-31
US20190134059A1 (en) 2019-05-09
IL285928A (en) 2021-10-31
JP7312523B2 (ja) 2023-07-21
AU2023203392A1 (en) 2023-06-29
IL285928B2 (en) 2025-06-01
KR102438425B1 (ko) 2022-09-01
RU2018142068A (ru) 2020-06-08
NZ747911A (en) 2025-03-28
IL285928B1 (en) 2025-02-01
JP2019516789A (ja) 2019-06-20
UA125514C2 (uk) 2022-04-13

Similar Documents

Publication Publication Date Title
EP3337517A4 (fr) Conjugués anticorps-médicaments anti-dll3 et méthodes d'utilisation
EP3402549A4 (fr) Compositions pour micro-aiguilles et méthodes d'utilisation de celles-ci
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
EP3429591A4 (fr) Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
EP3694529A4 (fr) Protéines trispécifiques et méthodes d'utilisation
MA49403A (fr) Compositions de pde5 et méthodes d'immunothérapie
MA48579A (fr) Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
EP3383430A4 (fr) Anticorps et leurs méthodes d'utilisation
EP3355954A4 (fr) Méthodes et compositions d'administration
EP3551209A4 (fr) Fusions d'insuline-fc et méthodes d'utilisation
EP3373969A4 (fr) Composés interagissant avec le glycane et méthodes d'utilisation
EP3328363A4 (fr) Compositions et méthodes d'immunomodulation
EP3383917A4 (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
MA44862A (fr) Formulations de fulvestrant et méthodes d'utilisation de celles-ci
EP3319611A4 (fr) Oxystérols et leurs méthodes d'utilisation
EP3474857A4 (fr) Compositions et méthodes de libération d'agents thérapeutiques
EP3525583A4 (fr) Anticorps anti-c1s et leurs méthodes d'utilisation
EP3436022A4 (fr) Oxystérols et leurs méthodes d'utilisation
EP3684819A4 (fr) Anticorps anti-ykl40 et méthodes d'utilisation
EP3728323A4 (fr) Anticorps anti-fzd et méthodes d'utilisation
MA43282A (fr) Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées
MA46422A (fr) Oligonucléotides modifiés et méthodes d'utilisation